WAINZUA (Eplontersen) Approved In The EU For The Treatment Of Hereditary Transthyretin-Mediated Amyloidosis In Adults With Stage 1 Or Stage 2 Polyneuropathy
ReutersMar 10, 2025 11:06 AM
March 10 (Reuters) - Ionis Pharmaceuticals Inc IONS.O:
WAINZUA (EPLONTERSEN) APPROVED IN THE EU FOR THE TREATMENT OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS WITH STAGE 1 OR STAGE 2 POLYNEUROPATHY
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
What Is Worldcoin? Why Did WLD Surge Suddenly, and What’s Next?
Worldcoin is evolving from a “hype token” into a foundational layer for global identity. Its fusion of biometrics, blockchain, and financial inclusion has earned growing recognition from users and institutions. If it can overcome technical hurdles, launch real-world payment use cases, and stabilizeTradingKey
Fri, Sep 12
U.S. August CPI Preview: Persistent Rise in Inflation, What Impact on Rate Cuts? And on US Stocks?
TradingKey - On 11 September 2025, the U.S. will publish August CPI data. Consensus forecasts indicate a 0.3% month-over-month increase for both headline CPI and core CPI. As a result, headline CPI year-over-year may climb to 2.9%, up from 2.7%TradingKey
Tue, Sep 9
Fed to Cut Rates: All Asset Prices Up!
TradingKey - The Federal Reserve is almost certain to restart its interest rate cut cycle on 17 September this year. After in-depth research, we have concluded that cryptocurrencies, the broader U.S. stock market, and short-term U.S. Treasury bonds will all go up.TradingKey
Mon, Sep 8
AppLovin Q2 FY2025 Earnings Review: AI-Fueled Surge Delivers Record Results—So Why Did the Stock Dip After Hours?
TradingKey - AppLovin (NASDAQ: APP) reported strong Q2 FY2025 earnings on August 6, 2025, driven by its AI-powered advertising platform, Axon 2.0, and the completion of its apps business divestiture. The company exceeded market expectations, although cautious guidance, concerns over long-term impactTradingKey
Thu, Aug 7
ASML Q2 FY2025 Earnings Review: Strong Growth and High-NA EUV Breakthrough Shadowed by 2026 Uncertainty
ASML Holding N.V. (NASDAQ: ASML) released its Q2 FY2025 earnings on July 16, 2025, exceeding market expectations with robust net sales and net bookings, though the stock fell around 10% due to cautious guidance for 2026 amid geopolitical uncertainties.TradingKey
Mon, Jul 14
Tradingkey
